Kura Oncology vs Arcus Biosciences
KURA and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KURA and RCUS compare
Arcus Biosciences is the larger company, worth 3.1 times as much as Kura Oncology ($2.1B against $666M).
Kura Oncology keeps more of each dollar of sales as profit, with a net margin of −369% compared with −393% at Arcus Biosciences.
Arcus Biosciences scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KURA | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $666M | $2.1B |
| Share price | $7.49 | $16.39 |
| Change, 1 year | −33.2% | −18.3% |
| Change, 5 years | −46.5% | −64.6% |
| Beta (5Y) | 2.30 | 1.13 |
| Employees | 260 | 601 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.4× (better) | 17.8× |
| P/B | 37.1× | 4.5× (better) |
| FCF yield | −13.4% (better) | −22.8% |
| Fair value | – | $7.34 |
| Margin of safety | – | −123% |
| Growth | ||
| Revenue growth (TTM) | – | −55.3% |
| Revenue growth, 5Y average | – | 25.9% |
| Profitability | ||
| Operating margin | −394% (better) | −415% |
| Net margin | −369% (better) | −393% |
| FCF margin | −112% (better) | −406% |
| Return on equity | −225% | −90.8% (better) |
| Financial health | ||
| Debt / equity | 0.55 | – |
| Interest coverage | −227.1× | −44.2× (better) |
| Current ratio | 3.60 | 3.82 (better) |
| Altman Z-score | −3.56 | −0.74 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −13.8% |
| Shareholder yield | 0.00% (better) | −13.8% |
| Ownership | ||
| Held by institutions | 98.0% | 96.3% |
| Held by insiders | 2.7% | 31.7% |
| Insider net buying, 12 months | $512K (better) | −$9.3M |
| Short interest, % of float | 14.6% | 15.2% |
Go deeper
- KURA stock overview
- KURA income statement
- KURA valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.